European regulators have accepted for review marketing authorisation applications for Hansa’s Idefirix and Astellas’ Xospata. More: EMA accepts marketing authorisation applications for Idefirix and Xospata Source: News
read moreThe first treatment for a rare disease characterised by high levels of triglycerides in blood is among eight new medicines put forward by the European Medicines Agency’a human medicines committee (CHMP) for approval. More: Eight medicines recommended in final London
read moreOral iron replacement therapy Feraccru has been shown to have comparable efficacy to intravenously delivered Ferinject in patients with Iron Deficiency Anaemia, offering a “real” alternative to hospital administration for many patients. More: Feraccru hits endpoints in anaemia trial Source:
read moreNHS Improvement and NHS England have shaken up their leadership team. More: Integrated NHS leadership team is ‘right move’ Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals